Lbmc Investment Advisors LLC Has $1.10 Million Stock Holdings in Johnson & Johnson $JNJ

Lbmc Investment Advisors LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,171 shares of the company’s stock after selling 459 shares during the quarter. Lbmc Investment Advisors LLC’s holdings in Johnson & Johnson were worth $1,095,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. StrongBox Wealth LLC grew its position in Johnson & Johnson by 3.4% during the second quarter. StrongBox Wealth LLC now owns 3,584 shares of the company’s stock worth $548,000 after buying an additional 118 shares in the last quarter. Aaron Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 3.8% during the second quarter. Aaron Wealth Advisors LLC now owns 20,826 shares of the company’s stock valued at $3,181,000 after purchasing an additional 753 shares in the last quarter. Divergent Planning LLC acquired a new stake in Johnson & Johnson during the second quarter valued at approximately $548,000. Balefire LLC boosted its holdings in Johnson & Johnson by 35.1% during the second quarter. Balefire LLC now owns 4,735 shares of the company’s stock valued at $723,000 after purchasing an additional 1,231 shares in the last quarter. Finally, Inspirion Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 45.1% during the second quarter. Inspirion Wealth Advisors LLC now owns 2,627 shares of the company’s stock valued at $401,000 after purchasing an additional 817 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $176.48 on Wednesday. The firm has a fifty day moving average of $171.67 and a two-hundred day moving average of $161.46. The stock has a market capitalization of $425.02 billion, a price-to-earnings ratio of 18.87, a PEG ratio of 2.26 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on JNJ shares. Bank of America lifted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Thursday, July 17th. Guggenheim reaffirmed a “neutral” rating and set a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.